Joseph Zouein
Overview
Explore the profile of Joseph Zouein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farhat M, Zouein J, Abou Khater J, Sarkis A, Helou J
Cureus
. 2025 Jan;
16(12):e76312.
PMID: 39850193
Subungual melanoma is a variant of acral lentiginous melanoma that arises from the nail matrix. Subungual melanomas present unique clinical challenges due to diagnostic difficulties and the lack of a...
2.
Zouein J, Naim N, Spencer D, Ortel T
Autoimmun Rev
. 2024 Dec;
24(2):103712.
PMID: 39617250
Background: Numerous genes have been associated with APS in the literature. In recent years, microRNA (miRNA) and long non-coding RNA (lncRNA) have also been shown to modulate the expression of...
3.
Kourie H, Zouein J, Zalaquett Z, Chebly A, Nasr L, El Karak F, et al.
Clin Res Hepatol Gastroenterol
. 2024 Jul;
48(8):102417.
PMID: 39009221
Background: The absence of KRAS and NRAS gene mutations (RAS wild type) in metastatic colorectal cancer (mCRC), is associated with a good response to targeted therapy with anti-EGFR receptor antibodies....
4.
Zouein J, Karam E, Strickler J, Kourie H
Target Oncol
. 2024 Jul;
19(5):705-710.
PMID: 38963654
Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) targeting HER2-positive malignancies across various tumor types. Through its unique composition, T-DXd achieves selective payload delivery, inducing cell death and halting tumor...
5.
Zouein J, Boueri M, Kourie H, Kattan J, Nemr E
Future Oncol
. 2023 Dec;
19(39):2565-2567.
PMID: 38084488
No abstract available.
6.
Kourie H, Zouein J, Succar B, Mardirossian A, Ahmadieh N, Chouery E, et al.
Oncol Rev
. 2023 Nov;
17:10603.
PMID: 38025894
Bladder cancer (BC) has been associated with genetic susceptibility. Single peptide polymorphisms (SNPs) can modulate BC susceptibility. A literature search was performed covering the period between January 2000 and October...
7.
Kourie H, Mahrous M, Naim N, Zouein J, Benbrahim Z, Rasul K, et al.
Future Oncol
. 2023 Aug;
19(21):1451-1459.
PMID: 37526151
Gastric cancer (GC) ranks as the fifth most prevalent cancer and the fourth deadliest cancer worldwide. In the Middle East and North Africa (MENA) region, GC represents about 4.8% of...
8.
Baz Y, Rassam M, Rhayem E, Zouein J, Gharios J, Kourie H
Immunotherapy
. 2023 May;
15(10):699-701.
PMID: 37139962
No abstract available.
9.
Abi-Aad S, Zouein J, Chartouni A, Naim N, Kourie H
Immunotherapy
. 2023 Apr;
15(8):611-618.
PMID: 37009648
Immunotherapy has improved the prognosis of many cancers, yet a large number of patients have demonstrated resistance to current immune checkpoint inhibitors. LAG-3 is an immune checkpoint expressed on tumor-infiltrating...
10.
Hachem S, Kassis Y, Hachem M, Zouein J, Gharios J, Kourie H
Biomark Med
. 2023 Mar;
17(1):51-57.
PMID: 36994675
Cholangiocarcinoma (CCA) is a rare malignancy with a very poor prognosis. Considering that most cases of CCA are diagnosed at a locally advanced stage and the standard of care for...